Alexandria Real Estate Equities, Inc. · ARE · Next earnings

Alexandria Real Estate Equities, Inc. reports Monday, Oct 26, 2026

ARE reports after market close with consensus EPS at $-0.03 and revenue at $433.4M. Last quarter: ARE Q1 2026: EPS Beats Estimates, Occupancy Slides to 87.7%, FFO Guidance Maintained

Reports After market close36 days awayDate estimated Real Estate

What the street expects

Consensus for the coming report
Consensus EPS $-0.03 Calendar consensus
Consensus revenue $433.4M Calendar consensus
Report date Oct 26, 2026 Monday, date estimated
Session After market close 36 days away

Where ARE left off: FY2026 Q1

Full report

ARE Q1 2026: EPS Beats Estimates, Occupancy Slides to 87.7%, FFO Guidance Maintained

EPS surprise +21.4% Reported $2.10 vs $1.73
Revenue surprise -4.6% Reported $653.0M vs $684.8M
Stock move -11.3% Event window
Subsequent drift +23.6% Up to 20 sessions

Management maintained 2026 FFO guidance at $6.40 per share, unchanged from prior expectations. Occupancy and same-property NOI outlook ranges were modestly lowered, reflecting the Q1 occupancy dip to 87.7% and large lease expirations. Capex outlook continues to decrease, consistent with the $2.9B disposition program. Q2 leasing target of 900,000-950,000 sf.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • FDA leadership and regulatory timeline uncertainty may constrain biotech tenant financing and leasing decisions
  • NIH budget and indirect-cost reimbursement policy volatility poses risk to life-science research funding
  • Large lease expirations in 2026-27 could create downtime and revenue gaps
  • Tenant wind-down reserve increased to $25-30M, signaling higher default risk
  • Capital market constraints continue to limit public biotech leasing demand

Questions analysts left open

  • Rationale for lowered occupancy guidance and assumptions behind the revised disposition asset mix
  • Impact of AI on future lab-space requirements; management views impact as neutral, contrary to some market expectations
  • Absence of public biotech leasing activity and implications for future demand recovery
  • Scale and timing of capitalized interest reductions
  • Potential for increased downtime from 2027 lease expirations

Ask FN2 about ARE next report

Transcript, numbers and history already loaded
What should I watch for in ARE's next earnings report?How did ARE guide last quarter, and is consensus above or below that?Give me the bull and bear case going into ARE earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the ARE recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent ARE quarters

All ARE earnings
-11.3%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.